Replies to post #6849 on GTC Biotherapeutics (fka GTCB)

[croumagnon]

Excellent explanation Dew, thanks.

"Given that 30% is the approximate rate of sDVT for this patient pool on placebo"

Do you know what is the approximate rate of sDVT for the plasma derived AT population? Also, is there any reason why we should think that ATryn should fare better than its plasma derived counterpart?